Searching targets for hepatocellular carcinoma (HCC) treatment, we identified zinc finger protein 191 (ZNF191) as a suppressor against HCC metastasis.
Introduction
Much due to the propensity for metastasis, HCC remains one of the leading fatal cancers 1 . Identifying prognostic markers and treatment targets for metastatic HCC is in urgent need.
With the complex progression of solid tumors, cancer cells gradually delaminated and intravasated 2 , both associating with loss of cell polarity 3 . The SCRIB-LGL-DLG complex is a conserved module in maintaining apical-basolateral polarity in both Drosophila and mammal cells 44, 5 . All its components are tumor suppressors in Drosophila 6 and predominantly inhibit cancer cell migration and metastasis 4, 7 . Nevertheless, how this complex is deregulated during tumor progression is scarcely known.
SCRIB-
LGL-DLG complex crosstalks with the Hippo-YAP signaling pathway which takes important part in HCC progression 4 . Accumulating clues strongly implicate the role of SCRIB-LGL-DLG complex as a negative regulator of YAP/TAZ signaling [8] [9] [10] [11] . ZNF191 (also called ZNF24) was previously identified as a proliferation promoter of HCC cells 12 . More than a transcription factor specifically recognizing TCAT repeating motifs 13 , it was also enriched at nascent DNA and facilitating DNA replication 14 . ZNF191 was even reported to facilitate the migration of endothelial cells 15 and vascular smooth muscle cells 16 . However, we further found that ZNF191 should be lost in metastatic HCCs. We have confirmed that ZNF191 is indeed a suppressor against cell migration and metastasis, meanwhile an inhibitor of YAP1. ZNF191 is a direct and specific transcriptional regulator of DLG1. The unexpected function of ZNF191 is mediated by a putative DLG1-YAP1 signaling.
Results

Down-regulation of ZNF191 associates with metastasis and poor clinical outcomes in HCC
We previously found ZNF191 was up-regulated in a subset of HCC specimens, promoting the proliferation of non-migratory L02 and Hep3B cells in vitro and in vivo 12 .
To further investigate the role of ZNF191in HCC progression, we collected a cohort of 120 HCC specimens with or without intrahepatic metastasis. We first identified a ZNF191 antibody that is suitable for Immunohistochemistry (IHC) ( Supplementary Fig. 1 ) and then applied this antibody to detect ZNF191 expression in these samples. By examining the correlation between ZNF191 expression and clinicopathological features ( Supplementary Table 1 ), we found ZNF191 was over-expressed in 73% HCC cases without metastasis but almost lost in 64% metastasis-present cases (Fig. 1a, b ). The inverse correlation was statistically significant (P < 0.01).
Accordingly, in the published databases we also found ZNF191 was over-expressed mainly in metastasis-free HCCs but down-regulated in HCCs with intrahepatic metastasis, distal metastasis (not significantly) or macroscopic vascular invasion ( Supplementary Fig. 2a-d) . Moreover, Kaplan-Meier analyses in TCGA database demonstrated that ZNF191 low expression predicts significantly shorter overall survival ( Supplementary Fig.   2e , f), further suggesting a potential use of ZNF191 as a favorable prognostic marker in HCC patients.
ZNF191 suppresses HCC cell migration in vitro and metastasis in vivo
Reduced or lost expression of ZNF191 in metastatic HCCs prompted us to investigate the role of ZNF191 in cell migration and invasion. To this end, we depleted ZNF191 in an array of HCC cell lines to test their migration ability. To our surprise, ZNF191 knockdown inhibited cell proliferation ( Fig. 1c ), but stimulated most of these HCC cell lines to migrate ( Fig. 1d & Supplementary   Fig. 4c-e ).
In wound-healing assays, the mixed effect of cell growth and migration was tested. ZNF191-knockdown SMMC-7721 cells recovered faster than control cells ( Fig. 1e ). Similarly, ZNF191 knockdown in MHCC-97H cells increased migration so that they should recover equally or faster than the control cells, considering ZNF191 knockdown had decreased growth in these cells ( Fig. 1c the panel below). We ectopically expressed ZNF191 using lentivirus in highly migratory HCC-LM3 cells (which express over 10 fold less ZNF191 than HepG2 cells, see Supplementary Fig. 4a , b) and ZNF191-knockdown MHCC-97H cells. All these treatments impaired cell motility ( Fig. 1f ). However, ZNF191 knockdown had no overt effect on the invasiveness of HCC cells ( Fig.   1d the panel below).
To further clarify the role of ZNF191 in HCC metastasis. ZNF191-knockdown MHCC-97H cells were orthotopically implanted into the livers of nude mice. 4 weeks and 8 weeks after implantation, in vivo imaging indicated that ZNF191 knockdown tumor-bearing mice suffered from smaller orthotopic tumors at first ( Fig. 2a ) but finally showed significantly more whole body spreading and more metastatic nodules in lungs than mice bearing control tumors ( Fig. 2a, d ), which was confirmed by tracing exogenous RFP marker under confocal microscope and histological examination (Fig.2b, c) . We further found ZNF191 knockdown resulted in more circulating tumor cells in mouse blood ( Fig. 2e ).
These findings indicate that ZNF191 inhibits HCC metastasis via suppressing primary tumor cells migration and intravasation.
ZNF191 suppresses cell migration independently of E-cadherin, β -catenin or VEGF
To explore the mechanisms underlying the metastasis-suppressive function of ZNF191, we first sought to determine whether epithelial-mesenchymal transition (EMT) had occurred after ZNF191 knockdown. We found that neither expression of E-cadherin nor N-cadherin was changed after ZNF191 knockdown ( Fig. 3a , b) Moreover, in our SMMC-7721 cells which lack expression of E-cadherin, ZNF191 knockdown still converted the cells from the round to the spindle-like shape and increased expression of Vimentin ( Supplementary Fig. 3a-c ), suggesting that the effect of ZNF191 on cell migration is independent of E-cadherin. β -catenin down-regulation was moderate in these cells after ZNF191 knockdown ( Fig. 3a, b ) and impossible to mediate the migration increase, because we confirmed that WNT3A orβ-catenin would promote rather than inhibit the migration of HepG2 cells ( Supplementary Fig. 6a, b ). ZNF191 was reported to suppress VEGF 17, 18 , but ZNF191 depletion still increased cell migration to the same fold when VEGF was blocked by Bevacizumab (AVASTIN), an inhibitor of VEGF-A ( Supplementary Fig. 6c ).
ZNF191 knockdown results in activation of YAP1 signaling
Incidentally, mining transcript profiling data in HEK293 cells 19 , we found that many well-studied target genes of the transcriptional co-activator YAP1 (CTGF, CYR61, EDN1 etc.) also happen to be the targets of ZNF191 ( Supplementary   Fig. 7a ). More intriguingly, in a database of 883 lines of cancer cells, ZNF191 expression is inversely correlated with almost all the prominent co-target genes of YAP1, including CTGF, CYR61 and EDN1 ( Supplementary Fig. 7d , e).
Indeed, our microarray data indicated that CTGF and CYR61 were significantly up-regulated upon ZNF191 knockdown in L02 cells ( Supplementary Fig. 7f ).
Considering the pro-metastasis role of YAP1 20,21 , we repeated the experiments and confirmed that YAP1 target genes were up-regulated after ZNF191 stable knockdown both in HEK293 ( Supplementary Fig. 7c ) and in HCC cell lines ( Fig. 3a ). These findings prompted us to determine whether YAP1 might be activated after ZNF191 knockdown. We demonstrated that phosphorylation of YAP1 at serine-127 was reduced after ZNF191 knockdown ( Fig. 3b ). In ZNF191 knockdown orthotopic tumors, consecutive sections showed more nuclear staining of YAP1, a hallmark of YAP1 activation, and less pYAP1 staining ( Fig. 3c ).
To determine whether ZNF191 suppresses metastasis through regulating YAP1, YAP1 signaling was blocked either by knocking down YAP1 or treating HepG2 cell with Verteporfin, a compound that disrupts YAP-TEAD complex 22 .
In both cases, migration of HepG2 cells was inhibited ( Fig. 3d , e); in YAP1-knockdown cells, depleting ZNF191 no longer stimulated migration ( Fig.   3d ). These data suggest that YAP1 activation takes an essential part in stimulating cell migration after ZNF191 knockdown.
DLG1 is the only candidate YAP1 regulator with its promoter directly targeted by ZNF191
Next we sought to determine how the YAP1 signaling is regulated by ZNF191.
To genome-widely identify the binding sites of ZNF191, chromatin immunoprecipitation-sequencing (ChIP-seq) was performed using a validated ZNF191 antibody ( Supplementary Fig. 8a ) in both HEK293 (where ZNF191 regulates YAP1 significantly) and HepG2 cells (a representative of HCC cells).
After peak calling, we identified 1315 ZNF191-bound peaks in HepG2 and 646 in HEK293 cells. In these peaks, we identified the most frequent motifs (Fig.   4a ). In HEK293 cells, the core motif TCAT triplicates match perfectly with the ZNF191 binding sites defined previously 13 ; while in HepG2 cells the core motif TSAW repeats (S = G or C; W = A or T) extend the known ZNF191 motif by limited tolerance in the second and fourth positions. These findings in turn qualified our ChIP-seq results. 235 peaks in HepG2 and 141 peaks in HEK293 cells locate in the 2,000 basepair regions up-stream of transcriptional start sites (TSSs) ( Supplementary Fig. 8b ). However, ZNF191-bound peaks were associated with neither YAP/TAZ signaling core elements (MST1/2, LATS1/2, YAP1/WWTR1, TEAD1/2/3/4) nor its down-stream target genes (CTGF, CYR61, EDN1 etc.).
DLG1, a component gene of the cell polarity module SCRIB-LGL-DLG, is an
indirect negative regulator of YAP1 ( Supplementary Fig. 8c, d ). We noticed that in both HEK293 and HepG2 cells, ZNF191 bound to the proximal promoter of DLG1. Although ZNF191 bound to other DLG family genes at their gene bodies in HepG2 ( Supplementary Fig. 8e ), DLG1 is the only known YAP1 regulator of which the promoter is targeted by ZNF191 in both cell lines.
In accordance with what we found, just near the summits of the ZNF191-bound peaks upstream DLG1 in both cells, we found a typical TCAT repeats (7 repeats in total, segmented by a TCGC, see Fig. 4b & Supplementary Fig. 8f ).
ChIP-qPCR confirmed that endogenous ZNF191 enriched around this motif ( Fig. 4c ). Electrophoretic mobility shift assay (EMSA) further indicated that recombinant ZNF191 protein directly bound to this sequence with high affinity.
When the repeating unit TCAT was mutated to ACAA, the binding affinity with ZNF191 almost disappeared ( Fig. 4d ). Accordingly, only the wild type DLG1
promoter was found to be activated by ZNF191 and when the TCAT repeats were deleted or mutated to ACAA repeats, ZNF191 failed to activate the reporter system in either SMMC-7721 or Hep3B cells (Fig. 4e ).
In HCC cells, ZNF191 knockdown resulted in a decrease of DLG1 expression while the other DLG family genes were largely not affected ( Fig. 5a, b ). And the reduction of DLG1 was confirmed in ZNF191 knockdown orthotopic tumors previously described ( Fig. 5c ). These findings indicate that ZNF191 directly activates the DLG1 promoter and maintained DLG1 expression in HCC cells.
DLG1 inhibits HCC cell migration and mediates the function of ZNF191
Firstly, DLG1 was confirmed to be a migration-suppressor in HCC cells via RNAi ( Fig. 5d ). DLG1 knockdown resulted in the reduction of YAP1 phosphorylation (S127) ( Fig. 5e ). Moreover, DLG1 knockdown partially compensated for the migration decrease caused by ZNF191 over-expression or rescue ( Supplementary Fig. 9f ). In DLG1-depleted MHCC-97H cells, ZNF191 knockdown was no longer able to increase cell migration as it did in control cells ( Fig. 5f , g). The similar result was observed in HepG2 cells ( Fig.   5g ), while DLG2 knockdown did not affect the migration-suppressive potential of ZNF191 ( Fig. 5f the bottom panels). These indicate that migration-suppressive function of ZNF191 is DLG1 dependent. Notably, in DLG1-knockdown cells, depleting ZNF191 no longer decreased YAP1 phosphorylation ( Fig. 5h ). These indicate that DLG1 is down-stream of ZNF191 and up-stream of YAP1.
ZNF191 expression correlates with DLG1 levels and inversely correlates with YAP1 activation in HCC
To validate our findings, we correlated among expression of ZNF191, DLG1 and YAP1 proteins using IHC in consecutive sections in a cohort of 120 HCC specimens. Nucleus YAP1 was found significantly correlated with intrahepatic metastasis (Fig. 6a ), and ZNF191 low expressing cases exhibited more nuclear staining of YAP1 (Fig. 6c ). These results support our model that ZNF191 loss induces metastasis through activating YAP1. Staining patterns of ZNF191 and DLG1 were similar ( Fig. 6d ); their mRNA levels in another 44 HCC samples correlated to each other significantly ( Fig. 6e ), which is further supported by TCGA data (Fig. 6f ). These observations support our model that ZNF191 maintains DLG1 transcription.
Although there are more DLG1 negative cases in YAP1 activating or metastasis cases, the correlation was neither significant statistically ( Fig. 6b and Supplementary Table 2 ). DLG1 negative was actually correlated with high serum AFP levels and larger tumor size ( Supplementary Table 2 ), indicating its tumor-suppressing function. This discrepancy implicates the existence of other mediator down-stream of ZNF191 and up-stream of YAP1.
Discussion
Findings from our present study and others imply duel functions of ZNF191 in cancer (Fig. 6h ). The model suggests that despite the pro-proliferation role, tumor cells would rather turn off ZNF191 expression in metastasis stage. Both the survival analysis in patents and in vivo experiments in mice confirmed that, although unfavorable for primary tumor growth, ZNF191 loss ultimately favors the dissemination of HCC cells to the whole body. Interestingly, DLG1, a bona fide target of ZNF191 identified in the current study, seems to be another 'Jekyll and Hyde' in tumor progression 23 . DLG1 accumulates in non-metastatic tumors but disappears in metastases 24 , sharing the same expression pattern as ZNF191 in HCC.
It was documented in Drosophila that lgl, scrib and dlg cooperated in a common genetic pathway 5 . lgl suppressed cell proliferation and survival via controlling hippo 9 ; scrib knockdown caused activation of Yki (homolog of mammal YAP1) 8 ; and dlg was found to suppress Yki in Drosophila follicle epithelial cells 11 and imaginal discs 8 . We showed that DLG1 knockdown in HCC cell lines HepG2 and MHCC-97H reduced YAP1 phosphorylation and blocked YAP1 from the regulation by ZNF191.
However, observations in HCC specimens failed to validate the association between DLG1 and YAP1 inactivation, but still confirmed the correlation between ZNF191 and YAP1 inactivation. These implicated alternative mechanisms that link ZNF191 and YAP1 signaling.
Screening binding factors of a critical element in MSLN promoter, ZNF191 was found co-localized with TEAD family members at an identical DNA motif 25 .
This cryptic fact implies that ZNF191 may regulate YAP1 target genes through affecting TEAD. However, this hypothesis has not been validated because our ChIP-seq results failed to identify ZNF191-bound peaks in promoters of CTGF, CYR61 or EDN1, where it should be occupied by TEADs 26 .
We demonstrated previously that ZNF191 activates the transcription of CTNNB1 in HCC 12 . In the present study we found that ZNF191 inhibits YAP1 activation. Sinceβ-catenin and YAP1 are generally redeemed over-lapped in functions and often co-existing 27 , our work has actually implied a paradox: If both regulations imposed by ZNF191 exist in HCC and functionally predominant, the activation of β -catenin and YAP1 should be mutually exclusive. Most intriguingly, a similar phenomenon, that nucleusβ-catenin and nucleus YAP1 tend to exclude each other (over-lapped in less than 4% HCC cases), has been observed in HCC in a recent study 28 .
Our research suggests that ZNF191 positive and negative HCCs are distinct in clinical outcomes and driven by different mechanisms. To treat HCC precisely in the future, β-catenin or YAP1 signaling has to be targeted respectively according to the disease context including ZNF191 status. Restoring ZNF191 expression while limiting its pro-proliferation effects is a challenge, but offers a chance to block metastasis specifically. Therefore, we identify a therapeutic target that could be harnessed to prevent HCC metastasis and favor patient survival. (a) ZNF191 expression levels in cancerous tissues were scored as higher or lower compared to non-cancerous liver tissues (also see Supplementary Fig.   1c ). Supplementary Fig. 4d, e ).
(e) Would-healing assays were applied to measure the mixed effects of cell growth and migration. Red fluorescence protein (RFP) is the tracing mark of these lentivirus transfected stable lines.
(f) Over-expressing ZNF191 in MHCC-97H and HCC-LM3 cells, or rescuing ZNF191 expression in ZNF191-knockdown MHCC-97H cells was performed using a lentivirus expressing a synonymously mutated ZNF191 CDS that is insensitive to ShZNF191-1 (ZNF191-SR), for details see Online Methods.
These cells were assayed for their migration abilities and representative results are shown. Statistic analysis of the results is in Supplementary Fig. 5a (c) ChIP-qPCR was performed. Apart from DLG1 promoter specific primers, primers specific to a region in DLG2 first intron (another ZNF191-bound peak in HepG2, see Supplementary Fig. 8e ) was also applied.
(d) ZNF191 recombinant protein was incubated with indicated probes for 20 minutes and subjected to electrophoretic mobility shift assay (EMSA).
(e) A portion of DLG1 promoter (wild type or deletion/mutant) was cloned to pGL3-luciferase vector, which was transfected with pCMV-Myc-ZNF191 and pRL-SV40 vectors into SMMC-7721 or Hep3B cells. 20 hours after transfection, cells were harvested and subjected to dual luciferase assays. (a) Also in Supplementary Fig. 10h . (h) The working model.
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Supplementary Discussion
ZNF191 regulates YAP1 target genes in opposite directions in HEK293 cells
In HEK293 cells, there seem to be a paradox that ZNF191 should regulate YAP1 target genes in opposite directions. When we knock-down ZNF191 transiently, as manipulated in the previous transcript profiling 1 , the CTGF mRNA will reduce ( Supplementary Fig. 7b ); but if we stably deplete ZNF191 using lentivirus, CTGF and other YAP1 target genes will increase expression ( Supplementary Fig. 7c ).
We have noticed that DLG shares a similar regulation pattern towards YAP 
CTGF is the marker of YAP1 activation, but unlikely the mediator of ZNF191's function
In HCC cells, ZNF191 inhibits YAP1 target genes including CTGF. But CTGF seems not mediate of the function of ZNF191, because: (a) CTGF protein levels were scarcely affected after ZNF191 knockdown in HepG2 cells (data not shown); (b) we found CTGF had minor or even inhibitory effects upon HepG2 migration ( Supplementary Fig. 6d, e ); (c) Verteporfin disrupts YAP-TEAD 3 and inhibits YAP1 target genes including CTGF 4 but did not interfere with ZNF191's migration-suppressing potential (Fig. 3e ). It seemed that ZNF191 inhibits cell migration by inactivating YAP1 but not CTGF. TAZ (also known as WWTR1) is functionally paralleled with YAP1 and promotes epithelial-mesenchymal transition 5 . Selecting YAP1 as representative of YAP/TAZ signaling, does not necessarily mean YAP1 and TAZ are regulated equally by ZNF191, since ZNF191 has not shown its influence on epithelial-mesenchymal transition. Further study is still needed to investigate to what extent that TAZ could be affected by ZNF191-DLG1 signaling.
The up-stream regulators of ZNF191
The regulators of ZNF191 remain elusive. We have noticed a very recent study, in searching for down-stream effectors of microRNA-940, ZNF191 was again found to be a suppressor of metastasis in gastric cancer with unclear mechanism 6 . This work not only supports our first finding (ZNF191 suppresses HCC metastasis) back to back, indicating that ZNF191 may be a general metastasis suppressor in a wider range of tumors, but also shed light onto the mechanisms controlling ZNF191 expression. We are interested to know whether microRNA-940 regulates ZNF191 in HCC. Considering the complex network of microRNA regulation, ZNF191 could be inhibited by means other than microRNA-940, finding regulators of ZNF191 at levels of transcription, pre-translation and post-translation is an inviting gap for future investigations.
Supplementary Figure Legends
Supplementary Figure 1 Validating the specificity of ZNF191 antibody for Immunohistochemistry (IHC).
(a) Fixed cells were incubated with rabbit polyclonal anti-ZNF191 antibody (from SIGMA, HPA024062) and detected by immunofluorescence. The effect of RNAi is validated in Supplementary Fig. 4b . After depleting ZNF191 using
RNAi, the fluorescence signal in the nuclei almost disappeared, leaving weak cytoplasm signal. Bar = 50 μm. Supporting Table 8 Results of statistic analysis in HCC specimens immunohistochemical staining of ZNF191 in HCC tissues.
For boldfaced probability value: P < 0.05.
Intrahepatic Metastasis means small HCC nodules such as venous permeation and tumor microsatellite nodules distributed around the primary (larger) HCC masses.
